nctId: NCT06373146 id: 18750 id: I8F-MC-GPIV type: OTHER domain: Eli Lilly and Company briefTitle: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-12 date: 2026-04 date: 2024-04-18 date: 2024-04-23 name: Eli Lilly and Company class: INDUSTRY name: Regeneron Pharmaceuticals briefSummary: The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 72 weeks and may include up to 19 visits. conditions: Obesity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 360 type: ESTIMATED name: Tirzepatide name: Mibavademab name: Tirzepatide-Placebo name: Mibavademab-Placebo measure: Mean Percent Change from Baseline in Body Weight measure: Mean Change from Baseline for Percent Change and Absolute Change in Body Weight (kg) measure: Mean Absolute Change from Baseline for Body Weight (kg) measure: Percentage of Participants Who Achieve ≥5% Body Weight Reduction measure: Percentage of Participants Who Achieve ≥10% Body Weight Reduction measure: Percentage of Participants Who Achieve ≥15% Body Weight Reduction measure: Percentage of Participants Who Achieve ≥20 Body Weight Reduction measure: Mean Percent Change from Randomization 2 for Body Weight measure: Mean Change from Randomization 2 for Body Weight (kg) measure: Mean Absolute Change from Randomization 2 for Body Weight (kg) measure: Change from Baseline to Week 24 in CoEQ Scores measure: Change from Baseline to Week 24 in CoEQ Scores measure: Change from Baseline in FCQ-T-r Scores measure: Change from Baseline in FCQ-T-r Scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Velocity Clinical Research, Gardena city: Gardena state: California zip: 90247 country: United States name: Mark T. Leibowitz role: PRINCIPAL_INVESTIGATOR lat: 33.88835 lon: -118.30896 facility: Irvine Clinical Research city: Irvine state: California zip: 92614 country: United States name: Elly R Lee role: PRINCIPAL_INVESTIGATOR lat: 33.66946 lon: -117.82311 facility: National Research Institute - Wilshire city: Los Angeles state: California zip: 90057 country: United States name: Juan Pablo Frias role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 facility: Velocity Clinical Research, North Hollywood city: North Hollywood state: California zip: 91606 country: United States name: Samuel Penziner role: PRINCIPAL_INVESTIGATOR lat: 34.17223 lon: -118.37897 facility: Velocity Clinical Research, Panorama City city: Panorama City state: California zip: 91402 country: United States name: Maricor Grio role: PRINCIPAL_INVESTIGATOR lat: 34.22473 lon: -118.44981 facility: Velocity Clinical Research, Santa Ana city: Santa Ana state: California zip: 92704 country: United States name: Julie Vu role: PRINCIPAL_INVESTIGATOR lat: 33.74557 lon: -117.86783 facility: Diablo Clinical Research, Inc. city: Walnut Creek state: California zip: 94598 country: United States name: Bonnie S. Kimmel role: PRINCIPAL_INVESTIGATOR lat: 37.90631 lon: -122.06496 facility: Solaris Clinical Research city: Meridian state: Idaho zip: 83646 country: United States name: David J. Butuk role: PRINCIPAL_INVESTIGATOR lat: 43.61211 lon: -116.39151 facility: Tandem Clinical Research city: Marrero state: Louisiana zip: 70072 country: United States name: Adil Fatakia role: PRINCIPAL_INVESTIGATOR lat: 29.89937 lon: -90.10035 facility: Velocity Clinical Research, Metairie city: Metairie state: Louisiana zip: 70006 country: United States name: Scott P Striplin role: PRINCIPAL_INVESTIGATOR lat: 29.98409 lon: -90.15285 facility: Velocity Clinical Research, Norfolk city: Norfolk state: Nebraska zip: 68701 country: United States name: Charles Harold Harper role: PRINCIPAL_INVESTIGATOR lat: 42.02834 lon: -97.417 facility: Lillestol Research city: Fargo state: North Dakota zip: 58104 country: United States name: Michael J Lillestol role: PRINCIPAL_INVESTIGATOR lat: 46.87719 lon: -96.7898 facility: South Texas Clinical Research city: Corpus Christi state: Texas zip: 78404 country: United States name: Lloyd Stegemann role: PRINCIPAL_INVESTIGATOR lat: 27.80058 lon: -97.39638 facility: Dallas Diabetes Research Center city: Dallas state: Texas zip: 75230 country: United States name: Julio Rosenstock role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 facility: Northwest Clinical Research Center city: Bellevue state: Washington zip: 98007 country: United States name: Nazia Rahman role: PRINCIPAL_INVESTIGATOR lat: 47.61038 lon: -122.20068 facility: Centro de Investigacion en Artritis y Osteoporosis SC city: Mexicali state: Baja California zip: 21200 country: Mexico name: Francisco Fidencio Cons Molina role: PRINCIPAL_INVESTIGATOR lat: 32.62781 lon: -115.45446 facility: Clínicos Asociados BOCM city: Mexico City state: Distrito Federal zip: 03300 country: Mexico name: Israel Olvera-Alvarez role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Unidad biomedica avanzada monterrey city: Monterrey state: Nuevo León zip: 64460 country: Mexico name: Raymundo Garcia Reza role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Medical Care and Research SA de CV city: Merida state: Yucatán zip: 97070 country: Mexico name: Carlos Eduardo Medina role: PRINCIPAL_INVESTIGATOR lat: 20.97537 lon: -89.61696 facility: Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos city: Chihuahua zip: 31110 country: Mexico name: Luis Alejandro Nevarez role: PRINCIPAL_INVESTIGATOR lat: 28.63528 lon: -106.08889 hasResults: False